236 related articles for article (PubMed ID: 36071033)
1. High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER
Palafox M; Monserrat L; Bellet M; Villacampa G; Gonzalez-Perez A; Oliveira M; Brasó-Maristany F; Ibrahimi N; Kannan S; Mina L; Herrera-Abreu MT; Òdena A; Sánchez-Guixé M; Capelán M; Azaro A; Bruna A; Rodríguez O; Guzmán M; Grueso J; Viaplana C; Hernández J; Su F; Lin K; Clarke RB; Caldas C; Arribas J; Michiels S; García-Sanz A; Turner NC; Prat A; Nuciforo P; Dienstmann R; Verma CS; Lopez-Bigas N; Scaltriti M; Arnedos M; Saura C; Serra V
Nat Commun; 2022 Sep; 13(1):5258. PubMed ID: 36071033
[TBL] [Abstract][Full Text] [Related]
2. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
3. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
4. Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
Xi J; Ma CX
Curr Oncol Rep; 2020 May; 22(6):57. PubMed ID: 32415339
[TBL] [Abstract][Full Text] [Related]
5. Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
O'Brien NA; McDermott MSJ; Conklin D; Luo T; Ayala R; Salgar S; Chau K; DiTomaso E; Babbar N; Su F; Gaither A; Hurvitz SA; Linnartz R; Rose K; Hirawat S; Slamon DJ
Breast Cancer Res; 2020 Aug; 22(1):89. PubMed ID: 32795346
[TBL] [Abstract][Full Text] [Related]
6. Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR
Sammons S; Shastry M; Dent S; Anders C; Hamilton E
Clin Breast Cancer; 2020 Feb; 20(1):1-11. PubMed ID: 31780379
[TBL] [Abstract][Full Text] [Related]
7. Decreased ER dependency after acquired resistance to CDK4/6 inhibitors.
Iida M; Toyosawa D; Nakamura M; Tsuboi K; Tokuda E; Niwa T; Ishida T; Hayashi SI
Breast Cancer; 2020 Sep; 27(5):963-972. PubMed ID: 32297248
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers.
Viswanadhapalli S; Ma S; Sareddy GR; Lee TK; Li M; Gilbreath C; Liu X; Luo Y; Pratap UP; Zhou M; Blatt EB; Kassees K; Arteaga C; Alluri P; Rao M; Weintraub ST; Tekmal RR; Ahn JM; Raj GV; Vadlamudi RK
Breast Cancer Res; 2019 Dec; 21(1):150. PubMed ID: 31878959
[TBL] [Abstract][Full Text] [Related]
9. Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.
Jansen VM; Bhola NE; Bauer JA; Formisano L; Lee KM; Hutchinson KE; Witkiewicz AK; Moore PD; Estrada MV; Sánchez V; Ericsson PG; Sanders ME; Pohlmann PR; Pishvaian MJ; Riddle DA; Dugger TC; Wei W; Knudsen ES; Arteaga CL
Cancer Res; 2017 May; 77(9):2488-2499. PubMed ID: 28249908
[TBL] [Abstract][Full Text] [Related]
10. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.
Shah AN; Cristofanilli M
Curr Treat Options Oncol; 2017 Jan; 18(1):6. PubMed ID: 28197838
[TBL] [Abstract][Full Text] [Related]
11. Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer.
Fang H; Huang D; Yang F; Guan X
Breast Cancer Res Treat; 2018 Apr; 168(2):287-297. PubMed ID: 29236235
[TBL] [Abstract][Full Text] [Related]
12. Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.
Herrera-Abreu MT; Palafox M; Asghar U; Rivas MA; Cutts RJ; Garcia-Murillas I; Pearson A; Guzman M; Rodriguez O; Grueso J; Bellet M; Cortés J; Elliott R; Pancholi S; Baselga J; Dowsett M; Martin LA; Turner NC; Serra V
Cancer Res; 2016 Apr; 76(8):2301-13. PubMed ID: 27020857
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer.
Dang F; Nie L; Zhou J; Shimizu K; Chu C; Wu Z; Fassl A; Ke S; Wang Y; Zhang J; Zhang T; Tu Z; Inuzuka H; Sicinski P; Bass AJ; Wei W
Nat Commun; 2021 Sep; 12(1):5386. PubMed ID: 34508104
[TBL] [Abstract][Full Text] [Related]
15. The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance.
Lawson M; Cureton N; Ros S; Cheraghchi-Bashi A; Urosevic J; D'Arcy S; Delpuech O; DuPont M; Fisher DI; Gangl ET; Lewis H; Trueman D; Wali N; Williamson SC; Moss J; Montaudon E; Derrien H; Marangoni E; Miragaia RJ; Gagrica S; Morentin-Gutierrez P; Moss TA; Maglennon G; Sutton D; Polanski R; Rosen A; Cairns J; Zhang P; Sánchez-Guixé M; Serra V; Critchlow SE; Scott JS; Lindemann JPO; Barry ST; Klinowska T; Morrow CJ; Carnevalli LS
Cancer Res; 2023 Dec; 83(23):3989-4004. PubMed ID: 37725704
[TBL] [Abstract][Full Text] [Related]
16. Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: Resistance mechanisms and novel treatment strategies.
Sharifi MN; Anandan A; Grogan P; O'Regan RM
Cancer; 2020 Aug; 126(15):3400-3416. PubMed ID: 32426848
[TBL] [Abstract][Full Text] [Related]
17. Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer.
Portman N; Alexandrou S; Carson E; Wang S; Lim E; Caldon CE
Endocr Relat Cancer; 2019 Jan; 26(1):R15-R30. PubMed ID: 30389903
[TBL] [Abstract][Full Text] [Related]
18. PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer.
Costa C; Wang Y; Ly A; Hosono Y; Murchie E; Walmsley CS; Huynh T; Healy C; Peterson R; Yanase S; Jakubik CT; Henderson LE; Damon LJ; Timonina D; Sanidas I; Pinto CJ; Mino-Kenudson M; Stone JR; Dyson NJ; Ellisen LW; Bardia A; Ebi H; Benes CH; Engelman JA; Juric D
Cancer Discov; 2020 Jan; 10(1):72-85. PubMed ID: 31594766
[TBL] [Abstract][Full Text] [Related]
19. Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer.
Scheidemann ER; Shajahan-Haq AN
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830174
[TBL] [Abstract][Full Text] [Related]
20. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]